Effectiveness and safety of a new vaginal misoprostol product specifically labeled for cervical ripening and labor induction

Cecatti, José Guilherme; Tedesco, Ricardo Porto; Pires, Helaine Maria Besteti; Calderon, Iracema de Mattos Paranhos; Faúndes, Aníbal

doi:10.1080/00016340500432580

Cited by 13 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Misoprostol is extensively used in obstetrics and has proved to be very effective cervical softening agent necessary intermination of pregnancy. [ 1 2 3 4 ] However, a similar beneficial effect of misoprostol on the nonpregnant uterus, will facilitate gynecological procedures that require cervical dilation such as endometrial biopsy, hysteroscopy, chromotubation, etc. Further the complications related to these procedures such as excessive pain, cervical injury may be reduced.…”

Section: Introductionmentioning

confidence: 99%

Effect of misoprostol for cervical priming before gynecological procedures on nonpregnant premenopausal women

et al. 2015

View full text Add to dashboard Cite

Background:Misoprostol is very effective in cervical ripening and is used for termination of pregnancy. A similar effect on the nonpregnant uterus will facilitate gynecological operations, and hence we assessed the effect of misoprostol on the nonpregnant uterus of premenopausal women.Materials and Methods:In a prospective double-blinded randomized controlled trial, 280 women were randomly allocated into two groups (12 women did not complete the intervention). Study (A) and control (B) group received 400 μg of misoprostol or 400 mg of metronidazole tablets (as a placebo) respectively in the posterior vaginal wall 6 h prior to gynecological procedures.Results:The mean cervical dilatation was significantly higher (P < 0.0001) in misoprostol compared to placebo group (4.6 ± 0.96 mm vs. 3.6 ± 0.82 mm), benefit were also observed on secondary outcome measures which were need for further dilatation, time taken for further dilatation, ease of dilatation, subjective assessment of pain by visual analog scale. Only 3.61% patients complained of intolerable pain during dilatation in the study group while in control group 48.74% complained of intolerable pain and required anesthesia. Most common side effects of misoprostol were abdominal pain and mild vaginal bleeding.Conclusion:Misoprostol was effective in cervical ripening of nonpregnant premenopausal uterus to facilitate gynecological procedures.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of misoprostol for cervical priming before gynecological procedures on nonpregnant premenopausal women

et al. 2015

View full text Add to dashboard Cite

show abstract

Vaginal misoprostol for cervical ripening and induction of labour

Hofmeyr

Gülmezoglu

Pileggi³

2010

Cochrane Database of Systematic Reviews

266

197

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2006

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Effectiveness and safety of a new vaginal misoprostol product specifically labeled for cervical ripening and labor induction

Abstract: The results showed that the 25-microg vaginal tablets of misoprostol were as effective and safe for cervical ripening and labor induction as the dose-equivalent fraction of 200-microg oral tablets.

Cited by 13 publications

References 16 publications

Effect of misoprostol for cervical priming before gynecological procedures on nonpregnant premenopausal women

Effect of misoprostol for cervical priming before gynecological procedures on nonpregnant premenopausal women

Vaginal misoprostol for cervical ripening and induction of labour

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About